No trial has shown PCSK9 inhibitors lower heart attack risk without statins
Louis stresses that Repatha and Praluent proved their benefit only on top of statins, so claims that they should replace statins are unsupported. They might work better but outcome data are lacking, which is why guidelines keep statins first-line and add PCSK9 inhibitors.




